Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

veltuzumab

A humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. Following binding, veltuzumab triggers… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the… Expand
  • table 1
  • table 2
Is this relevant?
2014
2014
IMPORTANCE B-cell depletion with the anti-CD20 antibody rituximab is highly effective for pemphigus vulgaris (PV) treatment… Expand
  • figure 1
  • figure 2
Is this relevant?
2011
2011
Background Subcutaneous injections of anti-CD20 antibodies may offer benefits to both patients and the healthcare system for… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Abstract 2788 Preclinical studies conducted at our institution (Alinari et al. Blood Abstract 1694, 2009) demonstrated superior… Expand
Is this relevant?
Review
2010
Review
2010
Veltuzumab is a humanized, anti-CD20 monoclonal IgG1 antibody (MAb), constructed recombinantly on the framework regions of… Expand
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating… Expand
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Veltuzumab is a humanized anti-CD20 monoclonal antibody with complementarity-determining regions (CDRs) identical to rituximab… Expand
  • table 1
  • table 2
Is this relevant?
2009
2009
Veltuzumab is a humanized, second-generation anti-CD20 mAb currently under development by Immunomedics Inc for the potential… Expand
Is this relevant?
2009
2009
We determined whether therapeutic responses using a bispecific antibody that pretargeted 90Y-hapten-peptide radioimmunotherapy or… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
2008
2008
Purpose: Antibodies are effective therapeutic agents in cancer, but cures are rarely if ever obtained. Combination therapies are… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?